These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15057662)

  • 1. Pirfenidone.
    Lasky J
    IDrugs; 2004 Feb; 7(2):166-72. PubMed ID: 15057662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
    Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
    Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban, an oral, direct inhibitor of activated Factor Xa.
    Shantsila E; Lip GY
    Curr Opin Investig Drugs; 2008 Sep; 9(9):1020-33. PubMed ID: 18729009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
    Azuma A
    Expert Rev Respir Med; 2010 Jun; 4(3):301-10. PubMed ID: 20524912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.
    Negri AL
    J Nephrol; 2004; 17(4):496-503. PubMed ID: 15372410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.
    Cho ME; Kopp JB
    Expert Opin Investig Drugs; 2010 Feb; 19(2):275-83. PubMed ID: 20050822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.
    Dosanjh A
    Transplant Proc; 2007 Sep; 39(7):2153-6. PubMed ID: 17889122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    Transplant Proc; 2005; 37(1):130-3. PubMed ID: 15808571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antioxidant role of pirfenidone in experimental cirrhosis.
    Salazar-Montes A; Ruiz-Corro L; López-Reyes A; Castrejón-Gómez E; Armendáriz-Borunda J
    Eur J Pharmacol; 2008 Oct; 595(1-3):69-77. PubMed ID: 18652820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers.
    Shi S; Wu J; Chen H; Chen H; Wu J; Zeng F
    J Clin Pharmacol; 2007 Oct; 47(10):1268-76. PubMed ID: 17906160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel treatment approaches to fibrosis in scleroderma.
    Distler J; Distler O
    Rheum Dis Clin North Am; 2008 Feb; 34(1):145-59; vii. PubMed ID: 18329537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    J Surg Res; 2005 May; 125(2):137-43. PubMed ID: 15854665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress in randomized clinical trials of antifibrotic drug nintedanib and pirfenidone].
    Li LX; Cheng YL; Shi JX
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2020 Feb; 38(2):147. PubMed ID: 32306682
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents.
    Chen J; Lu MM; Liu B; Chen Z; Li QB; Tao LJ; Hu GY
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2300-2. PubMed ID: 22342629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.
    Dosanjh A
    Eur J Pharmacol; 2006 May; 536(3):219-22. PubMed ID: 16581063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence.
    Aimo A; Cerbai E; Bartolucci G; Adamo L; Barison A; Lo Surdo G; Biagini S; Passino C; Emdin M
    Pharmacol Res; 2020 May; 155():104694. PubMed ID: 32061664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superoxide scavenging activity of pirfenidone-iron complex.
    Mitani Y; Sato K; Muramoto Y; Karakawa T; Kitamado M; Iwanaga T; Nabeshima T; Maruyama K; Nakagawa K; Ishida K; Sasamoto K
    Biochem Biophys Res Commun; 2008 Jul; 372(1):19-23. PubMed ID: 18468515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Idiopathic pulmonary fibrosis -- progress in sight].
    Kaarteenaho R; Hodgson U; Myllärniemi M
    Duodecim; 2011; 127(24):2639-45. PubMed ID: 22320106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis.
    Ammar YA; Ismail MM; El-Sehrawi HM; Noaman E; Bayomi AH; Shawer TZ
    Arch Pharm (Weinheim); 2006 Aug; 339(8):429-36. PubMed ID: 16832818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.